Skip to main navigation

Skip to Content

Menu

About Cerevel
Our Programs
Our Science
- Our scientific strategy
- Our pipeline
Investor & Media
Careers
- Working at Cerevel Therapeutics
- Open positions
Contact Us

Quarterly Results

Quarterly Results

Show all

2022

Q1

1Q 2022 Financial Results & Business Update 11.3 MB
Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
Form 10-Q

2021

Q4

4Q 2021 Financial Results & Business Update 7.9 MB
Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results
Form 10-K

Q3

Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates
3Q 2021 Financial Results & Business Update 4.5 MB
Form 10-Q

Q2

Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
Form 10-Q

Q1

Cerevel Therapeutics Reports First Quarter 2021 Financial Results and Business Updates
Form 10-Q

2020

Q4

Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2020 Financial Results
Form 10-K

Q3

Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights
Form 10-Q

Print

RSS Feeds

Email Alerts

Investor Contact

Search

Cerevel

About CerevelAbout Cerevel
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our ScienceOur Science
- Our scientific strategy
- Our pipeline
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- Darigabat
- CVL-231
- CVL-936
Investors & MediaInvestors & Media
- Overview
- News & Events
- Stock
- Financials
- Governance
- Resources
CareersCareers
- Working at Cerevel Therapeutics
- Open Positions
Contact Us

Facebook
Twitter
LinkedIn
YouTube

Cerevel

Terms of Use
Privacy Policy
FCOI
Early Access Program (EAP) Policy

© 2022 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of

Cerevel Therapeutics. All Rights Reserved.